98%
921
2 minutes
20
Background: A single, multitiered valve center designation has been proposed to publicly identify centers with expertise for all valve therapies. The correlation between transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) procedures is unknown.
Objectives: The authors sought to examine the relationship between site-level volumes and outcomes for TAVR and MTEER. We further explored variability between sites for MTEER outcomes.
Methods: Using the STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) national registry, TAVR and MTEER procedures at sites offering both therapies from 2013 to 2022 were examined. Sites were ranked into deciles of adjusted in-hospital and 30-day outcomes separately for TAVR and MTEER and compared. Stepwise, hierarchical multivariable models were constructed for MTEER outcomes, and the median OR was calculated.
Results: Between 2013 and 2022, 384,394 TAVRs and 53,274 MTEERs (median annualized volumes: 93.6 and 18.8, respectively) were performed across 453 U.S. sites. Annualized TAVR and MTEER volumes were moderately correlated (r = 0.48; P < 0.001). After adjustment, 14.3% of sites had the same decile rank for TAVR and MTEER 30-day composite outcome, 50.6% were within 2 decile ranks; 35% had more discordant outcomes for the 2 procedures (P = 0.0005). For MTEER procedures, the median OR for the 30-day composite outcome was 1.57 (95% CI: 1.51-1.64), indicating a 57% variability in outcome by site.
Conclusions: There is modest correlation between hospital-level volumes for TAVR and MTEER but low interprocedural correlation of outcomes. For similar patients, site-level variability for mortality/morbidity following MTEER was high. Factors influencing outcomes and "centers of excellence" as a whole may differ for TAVR and MTEER.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcin.2023.11.012 | DOI Listing |
JACC Case Rep
August 2025
Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Background: Transapical transcatheter aortic valve replacement (TA-TAVR) is a viable option for inoperable patients who are not eligible for a transfemoral route. Rarely, delayed complications such as primary mitral regurgitation (MR) may emerge owing to procedural factors.
Case Summary: An 85-year-old patient deemed at high surgical risk underwent TA-TAVR successfully for severe symptomatic aortic stenosis.
JACC Heart Fail
September 2025
Ascension Saint Thomas, Nashville, Tennessee, USA.
Background: Mitral transcatheter edge-to-edge repair (MTEER) is approved for patients with secondary mitral regurgitation (SMR) and heart failure based on COAPT (The Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy) eligibility criteria. Outcomes in patients beyond COAPT criteria with more advanced heart disease remain unclear.
Objectives: This study aimed to assess the outcomes of MTEER in SMR patients beyond COAPT trial criteria from the global, post-market EXPANDed studies.
J Clin Med
June 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Transcatheter mitral valve edge-to-edge repair (M-TEER) reduces mitral regurgitation (MR) severity and improves symptoms, but early post-procedural assessment of left atrial pressure (LAP) remains challenging. : Investigating the impact of M-TEER on diastolic parameters and derived cutoff values to estimate post-procedural LAP. : This retrospective study (n = 240) analyzed the effects of M-TEER on diastolic parameters.
View Article and Find Full Text PDFJACC Cardiovasc Interv
April 2025
Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
Background: The impact of mitral valve (MV) surgery type after failed mitral transcatheter edge-to-edge repair (M-TEER) has not been well studied.
Objectives: The aim of this study was to compare the outcomes of MV repair vs replacement after failed M-TEER.
Methods: From 2009 to 2020, a total of 332 patients across 34 centers from the CUTTING-EDGE registry underwent MV surgery after M-TEER.
AME Case Rep
November 2024
Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: There are few reports about the one-stage surgery of transcatheter aortic valve replacement (TAVR) + mitral valve transcatheter edge-to-edge repair (M-TEER) around the world. TAVR + M-TEER surgery is usually performed under the simultaneous guidance of digital subtraction angiography (DSA) and echocardiography. There is no report of TAVR surgery assisted only by echocardiography all over the world.
View Article and Find Full Text PDF